Evaluation Of 5-hydroxy-2,3-diaryl (substituted)-cyclopent-2-en-1-ones as cis-restricted analogues of combretastatin A-4 as novel anti angiogenic and anticancer agents Vinod Kumar SannaManu JaggiAnand C. Burman PRECLINICAL STUDIES 08 May 2009 Pages: 363 - 380
Development and pharmacologic characterization of deoxybromophospha sugar derivatives with antileukemic activity Satoki NakamuraMitsuji YamashitaKazunori Ohnishi PRECLINICAL STUDIES 14 May 2009 Pages: 381 - 391
The neem limonoids azadirachtin and nimbolide inhibit cell proliferation and induce apoptosis in an animal model of oral oncogenesis G. Harish KumarR. Vidya PriyadarsiniS. Nagini PRECLINICAL STUDIES 21 May 2009 Pages: 392 - 401
MER1, a novel organic arsenic derivative, has potent PML-RARα- independent cytotoxic activity against leukemia cells Mirna GolemovicAlfonso Quintás-CardamaSrdan Verstovsek PRECLINICAL STUDIES 26 May 2009 Pages: 402 - 412
The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines Brigette B. Y. MaVivian W. Y. LuiAnthony T. C. Chan PRECLINICAL STUDIES 27 May 2009 Pages: 413 - 420
Cytotoxic activities of new iron(III) and nickel(II) chelates of some S-methyl-thiosemicarbazones on K562 and ECV304 cells Belkıs AtaseverBahri ÜlküsevenZeynep Solakoğlu PRECLINICAL STUDIES 04 June 2009 Pages: 421 - 432
Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines D. M. CollinsJ. CrownR. O’Connor PRECLINICAL STUDIES 05 June 2009 Pages: 433 - 444
The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12 Eva RoubalováVeronika KvardováBořivoj Vojtěšek PRECLINICAL STUDIES 05 June 2009 Pages: 445 - 453
Synthesis and identification of a new class of (S)-2,6-diamino-4,5,6,7-tetrahydrobenzo[d]thiazole derivatives as potent antileukemic agents D. S. PrasannaC. V. KavithaK. S. Rangappa PRECLINICAL STUDIES 10 June 2009 Pages: 454 - 465
Tea polyphenols inhibit cyclooxygenase-2 expression and block activation of nuclear factor-kappa B and Akt in diethylnitrosoamine induced lung tumors in Swiss mice Preeti RoyNidhi NigamYogeshwer Shukla PRECLINICAL STUDIES 11 June 2009 Pages: 466 - 471
Pyrimidinyl-arylpropionic acid derivatives: viable resources in the development of new antineoplastic agents Xishan XiongLi WangChanglin Mei PRECLINICAL STUDIES 17 June 2009 Pages: 472 - 481
Purine analogs sensitize the multidrug resistant cell line (NCI-H460/R) to doxorubicin and stimulate the cell growth inhibitory effect of verapamil Milica PešićAna PodolskiSabera Ruždijić PRECLINICAL STUDIES 18 June 2009 Pages: 482 - 492
Novel combretastatin A-4 derivative XN0502 induces cell cycle arrest and apoptosis in A549 cells Hong ZhuJun ZhangQiaojun He PRECLINICAl STUDIES 30 March 2010 Pages: 493 - 501
Phase I trial of weekly docetaxel, weekly doxorubicin, daily oral cyclophosphamide, and G-CSF (ConTAC Regimen)in advanced malignancies Robert WesolowskiDavid PeereboomGeorge Thomas Budd PHASE I STUDIES 12 May 2009 Pages: 502 - 508
A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors Anne M. TraynorMichael S. GordonWilliam L. Read PHASE I STUDIES 13 May 2009 Pages: 509 - 515
Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma Byung Woog KangWon Seog KimCheolwon Suh PHASE II STUDIES 23 June 2009 Pages: 516 - 522
Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors Darren R. FeldmanStefan TurkulaRobert J. Motzer PHASE II STUDIES 23 June 2009 Pages: 523 - 528
Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients Antoine HollebecqueAntoine AdenisNicolas Penel SHORT REPORT 09 May 2009 Pages: 529 - 530
Reversible cardiogenic shock following 5-Fluorouracil infusion Charles FertéCarlos Gomez RocaStephane Ederhy SHORT REPORT 05 June 2009 Pages: 531 - 533